Speaker Profile
Distinguished Scientist, GRAIL
Biography
Eric A. Klein is a Distinguished Scientist at GRAIL. Previously he servedas the Andrew C. Novick Distinguished Professor and Chair of the GlickmanUrological and Kidney Institute and Lerner College of Medicine of theCleveland Clinic, where he was also a member of the Department of CancerBiology of the Cleveland Clinic Lerner Research Institute, the TaussigCancer Institute, and the Genitourinary Malignancies Program in the CaseComprehensive Cancer Center. Dr. Kleins clinical and research interestsfocused on prostate cancer with an emphasis on genomics and clinicaltrials. Most recently his work has focused on the clinical development ofmulticancer early detection tests. Dr. Klein was a Fellow in theDistinguished Careers Institute at Stanford University in 2022 and joinedGRAIL in 2023.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Victor Velculescu, Johns Hopkins University
PMWC Award Ceremony
• Klaus Pantel, University Medical Center Hamburg-Eppendorf / ELBS
• Daniel De Carvalho, University of Toronto
Keynote: Early Detection of Cancer by Multimodal Liquid Biopsy Analysis
• Klaus Pantel, UKE / ELBS
From Mutation to Methylation: The Next Wave of Liquid Biopsy Biomarkers
• Chair: Victor Velculescu, Johns Hopkins University
• Daniel De Carvalho, University of Toronto
• Manel Esteller, Sant Pau Research Institute
• Gordon Sanghera, Oxford Nanopore Technologies
Advancing Minimal Residual Disease Detection Through cfDNA & cfRNA Profiling
• Chair: Luis Diaz, Memorial Sloan Kettering Cancer Center
• Anne-Renee Hartman, Adela
• Klaus Pantel, UKE / ELBS
AI-Informed Biomarker Trials: Turning Early Signals into Actionable Designs
• Chair: Manish Kohli, University of Utah
• Luis Diaz, MSKCC
• Eric Klein, GRAIL
• Peter Bach, DELFI Diagnostics
• Samuel Levy, ClearNote Health
Role of AI in Liquid Biopsies & Cancer Detection
• Chair: Amoolya Singh, DELFI Diagnostics
• Matthew Baker, Dxcover
• Pankaj Vats, NVIDIA
Fragmentomics for Early Detection
• Varsha Rao, Claret Bioscience
Integrating Genetic Risk with Early Detection
• Giordano Botta, Allelica
Metagenomic Diagnostics & Global Pathogen Surveillance
• Charles Chiu, UCSF
AI-Driven Host–Pathogen Signatures from Plasma cfDNA
• Sivan Bercovici, Karius
Ultra-Sensitive Multimodal Liquid Biopsy for Early Cancer Detection
• Atul Sharan, CellMax Life
AI-Enhanced Proteomic Signatures for Early Cancer Detection
• Diana Abdueva, Aqtual
